Navigation Links
CMC Contrast Granted Orphan Drug Designation by the FDA for its Liver Specific MRI Contrast Media CMC-001
Date:11/27/2013

LUND, Sweden, November 27, 2013 /PRNewswire/ --

CMC Contrast AB, a privately owned drug development company that is developing a targeted contrast agent for Magnetic Resonance Imaging (MRI), announced today that Orphan Drug Designation has been granted by the US Food and Drug Administration (FDA) for its liver specific contrast agent CMC-001. The Orphan Drug Designation has been granted for CMC-001 for use as a targeted contrast agent for diagnostic MRI for detection and localization of focal liver lesions in patients where gadolinium-based contrast agents are contraindicated or cannot be administered.

Orphan Drug Designation is granted by the FDA Office of Orphan Drug Products to novel drugs intended to treat a rare disease or condition affecting fewer than 200,000 people in the U.S. The designation confers special incentives to the drug developer, including tax credits towards the cost of clinical trials, prescription drug user fee waivers and may entitle a period of seven years U.S market exclusivity upon FDA approval.

Magnus Corfitzen, Chairman of CMC Contrast AB "The diagnostic benefits of enhanced MRI liver imaging in detecting and localizing focal liver lesions are well established. However, a small subset of patient groups cannot undergo enhanced liver MRI procedures due to the risks of severe side effects associated with currently used gadolinium based contrast agents. For these patients, including patients with severe chronic renal insufficiency, important diagnostic information may be missed due to lack of contrast enhanced MRI. CMC-001 will allow radiologists to obtain the best possible diagnostic information in these subsets of patients, enabling clinicians to select the optimal treatment option for these patients. This is not possible today as clinicians only have access to data from an unenhanced imaging procedure on which they will base their disease management decisions for these patients"

The FDA decision to grant the Orphan Drug Designation to CMC-001 is an important milestone for CMC Contrast AB.  The company is now planning a pivotal phase III clinical program which in conjunction with the completed phase I and II clinical studies should enable CMC-001 to obtain regulatory approval and marketing authorization in the US. CMC-001 will then become available to patients in need of a liver MRI procedure for whom gadolinium based contrast agents are contraindicated or cannot be administered.

About CMC Contrast

CMC Contrast AB is a privately owned drug development company that specializes in developing targeted contrast agents for Magnetic Resonance Imaging (MRI). CMC Contrast AB's product CMC-001 is the world's first oral contrast agent for MRI of the liver. CMC-001 is an oral manganese-based contrast agent which enables safe liver enhancement in MRI, in patients for whom gadolinium based contrast agents are contraindicated or cannot be administered. A liver MRI scan is a specialized radiology procedure used to examine the liver to identify certain conditions or diseases which can be malignant cancerous or benign lesions.

CMC Contrast is based in Lund, Sweden, and funded by prominent VC investors including Sunstone Capital, Industrifonden and Øresund Healthcare. http://www.cmccontrast.com

Contact
Magnus Corfitzen
Chairman, CMC Contrast AB
Email: moc@cmccontrast.com
Tel: +45-40-80-48-63



'/>"/>
SOURCE CMC Contrast
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medical Imaging Markets: Contrast Agents
2. Radiopharmaceuticals and Contrast Media: Frost & Sullivan Predicts Market Growth in Europe
3. Diagnostic Imaging Covers Communicating Contrast Agent Risk
4. Contrasting Reimbursement Environments Result in Different Prescribing Patterns for Premium-Priced Therapies in China and South Korea
5. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
6. Broad Patent Protection Granted for iBio Immunomodulator
7. BiO2 Medical Granted CE Mark for the Angel™ Catheter, the First IVC Filter with a Prophylactic Use Indication
8. QRxPharma Granted Additional US Patent on MoxDuo®
9. Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
10. Unilife Granted Key U.S. Patent for Unifill Prefilled Syringe
11. Vomaris patent estate grows to six issued U.S. patents and three granted international patents with U.S. Pat. No. 8,224,439
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2017)... ROCKVILLE, Md. , Aug. 4, 2017 ... during or shortly after a physician/patient consult has long ... industry, and was a notable focus of the largest ...  This is according to healthcare market research firm Kalorama ... of care testing (POCT) offerings or related supplies and ...
(Date:8/2/2017)... 2017   Marshall County Hospital in Benton, Kentucky has ... of hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short for "total room ... pathogens such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:7/31/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO), has been named one ... by Crain,s Detroit Business . The annual ... three-year revenue growth. This year,s edition measures growth from 2013 ... the complete list, visit crainsdetroit.com/awards/fast_50/2017 .  ... said Phil Hagerman , CEO and chairman of Diplomat. ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... August 22, 2017 , ... ... is the creation of published author, Julianne Hale, a consultant for the Intelligence ... and counter-terrorism expert focusing on the Near East region. Julianne has written ...
(Date:8/22/2017)... North Carolina (PRWEB) , ... August 22, 2017 ... ... strategic advisor. Mr. Stewart is the Founder and Managing Member for t4 Leadership ... that have become critical to his definition of “success”: physician leadership development, servant ...
(Date:8/22/2017)... ... 22, 2017 , ... “Call Of Spiritual Duty”: a revelation in an era ... C.S. Lizarde. Growing up on the streets of North Visalia, California, Carlos Lizarde ... apply the Biblical keys to his life, he noticed immediately that opportunities and blessings ...
(Date:8/21/2017)... (PRWEB) , ... August 22, 2017 , ... PracticeMatch, a ... to help healthcare employers connect with physicians and advanced practitioners like nurse practitioners ... career fairs in August through November of this year. The online career fairs ...
(Date:8/21/2017)... ... August 22, 2017 , ... ... Stevens as a 2017-2018 inductee into its VIP Woman of the Year ... is the nation’s leading networking organization exclusively for professional women, boasting more than ...
Breaking Medicine News(10 mins):